Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 20/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 20/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 6/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 3/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0777 SCHEMBL1042961 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| Mk-0777 SCHEMBL12794058 | 0.95 | GABRG2 (0.90) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL12794136 | 0.91 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL6524060 | 0.91 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2654854 | 0.90 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2652749 | 0.90 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| Mk-0777 SCHEMBL12794096 | 0.87 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL5766639 | 0.87 | GABRG2 (0.76) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL2655126 | 0.85 | GABRG2 (0.75) | GABRG2GABRB3GABRA3GABRA1GABRA2 | |
| SCHEMBL12794146 | 0.84 | GABRG2 (0.73) | GABRG2GABRB3GABRA3GABRA1GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | claimed |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| US-12617794-B2 | GABAA positive allosteric modulator compounds, methods of making, and uses thereof | NEUROCYCLE THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| EP-3856342-B1 | BICYCLIC DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2025-12-10 | — | — | EP | disclosed |
| US-12433898-B2 | Use of GABAA receptor modulators for treatment of itch | UNIVERSITAT ZURICH (CH) | 2025-10-07 | — | — | US | disclosed |
| US-20250268912-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | UNIVERSITAT ZURICH (CH) | 2025-08-28 | — | — | US | disclosed |
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2025-07-29 | — | — | US | disclosed |
| CN-115348962-A | As GABA A Naphthyridines and pyrido [3,4-c ] of alpha 5 receptor modulators]Pyridazine derivatives | 吉瑞工厂 | 2022-11-15 | — | — | CN | disclosed |
| WO-2022234271-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2022-11-03 | — | — | US | disclosed |
| CN-115003301-A | By GABA A Treatment of epileptic conditions with receptor modulators | 纽罗塞克医疗公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-4048266-A1 | TREATMENT OF EPILEPTIC CONDITIONS WITH GABAa RECEPTOR MODULATORS | Neurocycle Therapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-4048672-A1 | GABAA POSITIVE ALLOSTERIC MODULATOR COMPOUNDS, METHODS OF MAKING, AND USES THEREOF | Neurocycle Therapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-4039258-A1 | USE OF DIAZEPAM AS ONLY TOLERATED BENZODIAZEPINE RECEPTOR AGONIST IN COVID-19 PATIENTS | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2022-08-10 | — | — | EP | disclosed |
| EP-4017874-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | Coda Biotherapeutics, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220152037-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN | NEUROCYCLE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | GABRA5, GABRA1, GABRB1 | GABRG2 13/4885GABRB3 7/4885GABRA3 4/4885 |
| US-12617794-B2 | GABAA positive allosteric modulator compounds, methods of making, and uses thereof | GABRP, GABRB3, GABRB2 | GABRG2 11/4885GABRB3 2/4885GABRA3 5/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | GABRG2 15/4885GABRB3 6/4885GABRA3 5/4885 |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | HTR1D, HTR5A, PCNP | GABRG2 3641/4885GABRB3 1766/4885GABRA3 2464/4885 |
| US-20250268912-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | GABRB2, GABRB3, GABRB1 | GABRG2 8/4885GABRB3 2/4885GABRA3 9/4885 |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | FLNB, SETD1B, HTR5A | GABRG2 2547/4885GABRB3 701/4885GABRA3 1624/4885 |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | GABRG2 104/4885GABRB3 98/4885GABRA3 100/4885 |
| US-20220152037-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN | GABRB2, GABRB1, GABBR1 | GABRG2 15/4885GABRB3 4/4885GABRA3 11/4885 |
| US-12433898-B2 | Use of GABAA receptor modulators for treatment of itch | GABRB2, GABRB3, GABRB1 | GABRG2 8/4885GABRB3 2/4885GABRA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.